Phase II Study of LM-24C5
This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor
| Condition(s) | Advanced Solid Tumor Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor |
| Who can participate | Inclusion Criteria: 1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure. 2. Aged 18-80 years old (including boundary values) , male or female. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Life expectancy ≥ 3 months. 5. Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, or currently lack or are intolerant of, standard therapy. 6. CEACAM5-positive subjects. 7. At least one evaluable lesion. 8. Subjects must show appropriate organ and marrow function inlaboratory examinations within 7 days prior to the first dose. 9. Subjects who can communicate well with investigators and understand and adhere to the requirements of this study. Exclusion |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | LaNova Medicines Limited |
| Locations | Fuzhou, Fujian, China; Shanghai, Shanghai Municipality, China |
| Start date | 2025-12-15 |
| NCT ID | NCT07387081 |
| Official listing | https://clinicaltrials.gov/study/NCT07387081 |